Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Common Equity (2020 - 2025)

Historic Common Equity for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $378.6 million.

  • Cytek Biosciences' Common Equity fell 178.8% to $378.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.6 million, marking a year-over-year decrease of 178.8%. This contributed to the annual value of $395.7 million for FY2024, which is 68.0% up from last year.
  • Latest data reveals that Cytek Biosciences reported Common Equity of $378.6 million as of Q3 2025, which was down 178.8% from $377.6 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Common Equity registered a high of $425.5 million during Q4 2022, and its lowest value of -$11.0 million during Q2 2021.
  • Over the past 5 years, Cytek Biosciences' median Common Equity value was $399.5 million (recorded in 2021), while the average stood at $378.5 million.
  • In the last 5 years, Cytek Biosciences' Common Equity surged by 384264.0% in 2022 and then crashed by 826.44% in 2024.
  • Cytek Biosciences' Common Equity (Quarter) stood at $405.4 million in 2021, then rose by 4.97% to $425.5 million in 2022, then fell by 7.63% to $393.1 million in 2023, then grew by 0.68% to $395.7 million in 2024, then fell by 4.34% to $378.6 million in 2025.
  • Its Common Equity stands at $378.6 million for Q3 2025, versus $377.6 million for Q2 2025 and $379.6 million for Q1 2025.